Scholarlink

Background <p>Existing prognostic models for breast cancer (BC) brain metastases (BM) overlook neurological symptoms. Thus, we explored the incidence and prognostic relevance of neurological symptoms in a real-world cohort of BC patients with BM.</p> Methods <p>The Vienna Brain Metastasis Registry identified BC patients with BM between 1992 and 2020, categorised by subtype: hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−), HER2 overexpressing (HER2+), and triple-negative (TN).</p> Results <p>A total of 716 patients with BM from BC were included. In total, 80% (573/716) of the patients presented with neurological symptoms at BM diagnosis. Across all BC subtypes, asymptomatic patients presented with a significantly longer median OS from diagnosis of BM compared to symptomatic patients (<i>p</i> &lt; 0.05; log-rank test; HR+ BC 29 vs. 9 months; HER2+ BC 24 vs. 12 months; TN 12 vs. 6 months). In multivariate analysis with the BC-specific Graded Prognostic Assessment (Breast-GPA: HR:1.4; 95% CI:1.3–1.5; <i>p</i> &lt; 0.001), the presence of neurological symptoms at diagnosis (HR:1.6; 95% CI: 1.4–1.9; <i>p</i> &lt; 0.001) presented as independently associated with OS from time of BM diagnosis, respectively.</p> Conclusions <p>Neurological burden at BM diagnosis independently predicts survival in BC patients. Our findings emphasise incorporating the symptom status in the prognostic evaluation and reassessing BM screening in high-risk patients during prospective clinical trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月1日

查看全文
  • Ariane Steindl,
  • Clara Zach,
  • Luzia Berchtold,
  • Anna Grisold,
  • Brigitte Gatterbauer,
  • Franziska Eckert,
  • Zsuzsanna Bago-Horvath,
  • Johannes A. Hainfellner,
  • Ruth Exner,
  • Florian Fitzal,
  • Georg Pfeiler,
  • Christian F. Singer,
  • Georg Widhalm,
  • Rupert Bartsch,
  • Matthias Preusser,
  • Anna S. Berghoff

摘要

Background

Existing prognostic models for breast cancer (BC) brain metastases (BM) overlook neurological symptoms. Thus, we explored the incidence and prognostic relevance of neurological symptoms in a real-world cohort of BC patients with BM.

Methods

The Vienna Brain Metastasis Registry identified BC patients with BM between 1992 and 2020, categorised by subtype: hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−), HER2 overexpressing (HER2+), and triple-negative (TN).

Results

A total of 716 patients with BM from BC were included. In total, 80% (573/716) of the patients presented with neurological symptoms at BM diagnosis. Across all BC subtypes, asymptomatic patients presented with a significantly longer median OS from diagnosis of BM compared to symptomatic patients (p < 0.05; log-rank test; HR+ BC 29 vs. 9 months; HER2+ BC 24 vs. 12 months; TN 12 vs. 6 months). In multivariate analysis with the BC-specific Graded Prognostic Assessment (Breast-GPA: HR:1.4; 95% CI:1.3–1.5; p < 0.001), the presence of neurological symptoms at diagnosis (HR:1.6; 95% CI: 1.4–1.9; p < 0.001) presented as independently associated with OS from time of BM diagnosis, respectively.

Conclusions

Neurological burden at BM diagnosis independently predicts survival in BC patients. Our findings emphasise incorporating the symptom status in the prognostic evaluation and reassessing BM screening in high-risk patients during prospective clinical trials.